Security key
29337E102
Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN)
CUSIP: 29337E102
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Total 13F shares
- 62,391,024
- Total 13F value
- $960,824,930
- Share change
- +2,259,081
- SEC-reported price per share
- $15.40
- Number of holders
- 125
- Value change
- +$20,216,707
- Number of buys
- 61
- Number of sells
- 70
- Shares outstanding
- 59,773,132
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
125
Top holders
10
ELVN full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Enliven Therapeutics, Inc. SEC filings
Enliven Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 29337E102
Recent filing periods:
Ownership snapshot
Top reported holders of ELVN - Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
30 Sep 2025
3/4/5
13D/G
13F
Lead comparable stake: 13%
13D/G row: ORBIMED ADVISORS LLC
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 13%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
13%
FMR LLC
13%
BlackRock, Inc.
5.1%
Commodore Capital LP
7.9%
Fairmount Funds Management LLC
6.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
3/4/5
13D/G
13F
Director, 10%+ Owner · Company
|
13%
from 13D/G
|
$169,666,547
7,663,349 shares
|
— | 16 May 2024 |
| FMR LLC |
13D/G
13F
Company
|
13%
|
$161,103,383
7,870,219 shares
|
$0 | 30 Sep 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.1%
from 13D/G
|
$72,024,186
3,518,524 shares
|
— | 30 Sep 2025 |
| Commodore Capital LP |
13F
3/4/5
Company · 10%+ Owner
|
7.9%
|
$96,061,800
4,692,809 shares
|
— | 30 Sep 2025 |
| Fairmount Funds Management LLC |
13F
Company
|
6.2%
|
$75,973,259
3,711,444 shares
|
— | 30 Sep 2025 |
| Venrock Adviser, LLC |
13F
Company
|
5.4%
|
$66,042,996
3,226,331 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
125
Shares
62,391,024
Rows available
125
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
132
Q4 2025 holders
125
Holder diff
-7
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend